BRCA 2 - deficient sarcomatoid mammary tumors exhibit multi - drug resistance 1
نویسندگان
چکیده
BRCA2-deficient sarcomatoid mammary tumors exhibit multi-drug resistance 1 Janneke E. Jaspers, Wendy Sol, Ariena Kersbergen, Andreas Schlicker, Charlotte Guyader, 2 Guotai Xu, Lodewyk Wessels, Piet Borst, Jos Jonkers, Sven Rottenberg 3 4 Authors’ affiliations 5 1 Divisions of Molecular Oncology, 2 Molecular Pathology and 3 Molecular Carcinogenesis, 6 Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; Institute of 7 Animal Pathology, Vetsuisse Faculty, University of Bern, Laengassstrasse 122, 3012 Bern, Switzerland 8 9 Running title 10 Multi-drug resistance of sarcomatoid mouse mammary tumors 11 12 Precis 13 Epithelial-to-mesenchymal transition in murine mammary tumors associates with an 14 acquisition of multi-drug resistance, due to increased expression of genes encoding drug 15 efflux transporters. 16 17
منابع مشابه
BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.
Pan- or multidrug resistance is a central problem in clinical oncology. Here, we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP inhibition. We found that multidrug resistance was strongly associated with an EMT-like sarcomatoid phenotype and high expression of the Abcb1b gene, which encodes...
متن کاملLack of ABCG 2 shortens latency of BRCA 1 - deficient mammary tumors and this is not 1 affected by genistein or resveratrol 2 3
Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not 1 affected by genistein or resveratrol 2 3 Serge A.L. Zander, Ariena Kersbergen, Wendy Sol, Maaike Gonggrijp, Koen van de Wetering, Jos Jonkers, 4 Piet Borst, Sven Rottenberg 5 6 Authors’ affiliations: 7 Divisions of Molecular Oncology and Molecular Pathology, The Netherlands Cancer Institute (Antoni van 8 Leeuwenh...
متن کاملThe Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
BRCA1 and BRCA2 mutations are responsible for most familial breast carcinomas. Recent reports carried out in non-cancerous mouse BRCA1- or BRCA2-deficient embryonic stem (ES) cells, and hamster BRCA2-deficient cells have demonstrated that the targeted inhibition of poly(ADP-ribose) polymerase (PARP-1) kills BRCA mutant cells with high specificity. Although these studies bring hope for BRCA muta...
متن کاملPARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
Recent studies demonstrated that PARP-1 [poly(ADP-ribose) polymerase-1] inhibitors kill breast cancer associated gene-1 and -2 (BRCA1/2) deficient cells with extremely high efficiency while BRCA+/- and BRCA+/+ cells are relatively non-responsive to the treatment. It was therefore proposed that PARP-1 inhibitors might be the long-sought genetically specific drugs that are both safe and effective...
متن کاملA high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.
PURPOSE Hereditary breast cancer is partly explained by germline mutations in BRCA1 and BRCA2. Although patients carry heterozygous mutations, their tumors have typically lost the remaining wild-type allele. Selectively targeting BRCA deficiency may therefore constitute an important therapeutic approach. Clinical trials applying this principle are underway, but it is unknown whether the compoun...
متن کامل